Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SCYNEXIS Inc SCYX

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.


NDAQ:SCYX - Post by User

Comment by dmacdon Jul 30, 2021 12:34pm
55 Views
Post# 33632438

RE:Short Interest...

RE:Short Interest...Shorters might have their way for now but once sales start to roll out then they will pay up. There cannot be a lot of downside to warrant taking on the risk of upside on positive roll out news. The company does not need to raise any more cash so max downside might be $6.50/sh and then longs like me will start to load up even more, although I am already overweighted in SCYX. I see 10x potential here within 1.5 to 2.0 years as sales start to build, and 20x within 5 years. Q2 will not have any sales, and Q3 is manufacturing and sales ramp up so the losses will be higher than one might expect so maybe that will be the time to buy. It is too early for prediction on profitability but my guess is this time next year will be already be there or close to it and sales will be growing at a fast pace. It is sort of ridiculous that the market has not built in a probability of success here, but that gives those that probably know better a chance to accummulate. The risk / reward is very attractive at these prices if you ask me. 
<< Previous
Bullboard Posts
Next >>